In addition to small molecule inhibitors, docetaxel-conjugated nanoparticles that deplete αSMA+ myofibroblasts (or otherwise unspecified stromal cell populations), have also been developed; animal models of breast and pancreatic cancer have demonstrated that these approaches reduce tumor collagen I content, improve tumor perfusion, and reduce metastatic burden [106,107,108,109]. Here, ACTA1 is linked to neoplasm.